Symbols / CSTL Stock $18.88 +4.02% Castle Biosciences, Inc.

Healthcare • Diagnostics & Research • United States • NGM
CSTL (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Diagnostics & Research
CEO Mr. Derek J. Maetzold
Exch · Country NGM · United States
Market Cap 572.63M
Enterprise Value 325.53M
Income -12.83M
Sales 339.92M
FCF (ttm) 12.89M
Book/sh 15.23
Cash/sh 8.63
Employees 942
Insider 10d —
IPO Jul 25, 2019
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -20.95
PEG —
P/S 1.68
P/B 1.24
P/C —
EV/EBITDA -17.74
EV/Sales 0.96
Quick Ratio 6.26
Current Ratio 6.75
Debt/Eq 7.96
LT Debt/Eq —
EPS (ttm) -0.42
EPS next Y -0.90
EPS Growth —
Revenue Growth -4.90%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-03
Earnings (prior) 2026-05-06
ROA -3.96%
ROE -2.85%
ROIC —
Gross Margin 77.88%
Oper. Margin -22.00%
Profit Margin -3.78%
Shs Outstand 30.33M
Shs Float 25.78M
Insider Own 2.38%
Instit Own 91.20%
Short Float 4.83%
Short Ratio 4.77
Short Interest 1.43M
52W High 44.28
vs 52W High -57.36%
52W Low 14.59
vs 52W Low 29.40%
Beta 1.11
Impl. Vol. 1.79%
Rel Volume 1.53
Avg Volume 404.11K
Volume 620.04K
Target (mean) $47.12
Tgt Median $48.50
Tgt Low $40.00
Tgt High $52.00
# Analysts 8
Recom Strong_buy
Prev Close $18.15
Price $18.88
Change 4.02%
About

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$47.13
Mean price target
2. Current target
$18.88
Latest analyst target
3. DCF / Fair value
$7.65
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$18.88
Low
$40.00
High
$52.00
Mean
$47.13

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-13 main BTIG Buy → Buy $40
2026-05-07 main Baird Outperform → Outperform $43
2026-04-20 main Canaccord Genuity Buy → Buy $40
2026-02-27 main Baird Outperform → Outperform $44
2026-01-26 main Guggenheim Buy → Buy $47
2026-01-12 main Lake Street Buy → Buy $52
2026-01-05 main Guggenheim Buy → Buy $43
2025-12-22 main Canaccord Genuity Buy → Buy $50
2025-12-12 main BTIG Buy → Buy $50
2025-11-05 main BTIG Buy → Buy $38
2025-11-04 main Baird Outperform → Outperform $41
2025-09-09 main Canaccord Genuity Buy → Buy $37
2025-05-21 main Scotiabank Sector Outperform → Sector Outperform $40
2025-05-06 main Lake Street Buy → Buy $35
2025-05-06 main Canaccord Genuity Buy → Buy $37
2025-02-28 main Baird Outperform → Outperform $37
2025-01-02 reit Stephens & Co. Overweight → Overweight $41
2024-11-06 main Scotiabank Sector Outperform → Sector Outperform $44
2024-11-05 main Lake Street Buy → Buy $40
2024-11-05 main Keybanc Overweight → Overweight $36
News
RSS: Latest CSTL news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-07 MAETZOLD DEREK J Chief Executive Officer — 9,836 $22.08 $217,904
2026-05-07 MAETZOLD DEREK J Chief Executive Officer — 6,214 $2.39 $14,851
2026-04-21 MAETZOLD DEREK J Chief Executive Officer — 4,172 $25.10 $104,709
2026-04-21 MAETZOLD DEREK J Chief Executive Officer — 550 $2.39 $1,314
2026-04-06 MAETZOLD DEREK J Chief Executive Officer — 9,836 $25.03 $246,195
2026-04-06 MAETZOLD DEREK J Chief Executive Officer — 6,214 $2.39 $14,851
2026-03-26 MAETZOLD DEREK J Chief Executive Officer — 4,172 $25.55 $106,599
2026-03-26 MAETZOLD DEREK J Chief Executive Officer — 550 $2.39 $1,314
2026-03-26 COTTON RODNEY Director — 5,329 — —
2026-03-18 MAETZOLD DEREK J Chief Executive Officer — 19,300 $25.39 $500,098
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
344.23
+3.66%
332.07
+51.09%
219.79
+60.38%
137.04
Operating Revenue
344.23
+3.66%
332.07
+51.09%
219.79
+60.38%
137.04
Cost Of Revenue
71.03
+17.98%
60.20
+33.84%
44.98
+40.53%
32.01
Reconciled Cost Of Revenue
65.09
+17.68%
55.31
+32.76%
41.66
+40.14%
29.73
Gross Profit
273.20
+0.49%
271.86
+55.52%
174.81
+66.43%
105.03
Operating Expense
316.01
+20.07%
263.19
+8.41%
242.78
+23.76%
196.17
Research And Development
51.85
-0.37%
52.04
-2.94%
53.62
+19.41%
44.90
Selling General And Administration
229.32
+14.63%
200.05
+11.04%
180.15
+25.98%
143.00
Selling And Marketing Expense
138.12
+11.86%
123.47
+8.63%
113.66
+31.23%
86.61
General And Administrative Expense
91.21
+19.10%
76.58
+15.17%
66.50
+17.91%
56.40
Other Gand A
91.21
+19.10%
76.58
+15.17%
66.50
+17.91%
56.40
Total Expenses
387.04
+19.68%
323.40
+12.38%
287.76
+26.11%
228.18
Operating Income
-42.81
-593.77%
8.67
+112.75%
-67.98
+25.42%
-91.14
Total Operating Income As Reported
-42.81
-593.77%
8.67
+112.75%
-67.98
+6.70%
-72.86
EBITDA
11.34
-70.26%
38.14
+184.71%
-45.02
+22.83%
-58.34
Normalized EBITDA
9.88
-73.72%
37.58
+183.47%
-45.02
+41.25%
-76.63
Reconciled Depreciation
40.77
+154.87%
16.00
+29.74%
12.33
+16.95%
10.54
EBIT
-29.43
-232.91%
22.14
+138.60%
-57.35
+16.74%
-68.89
Total Unusual Items
1.47
+164.14%
0.56
0.00
-100.00%
18.29
Total Unusual Items Excluding Goodwill
1.47
+164.14%
0.56
0.00
-100.00%
18.29
Special Income Charges
—
0.00
0.00
-100.00%
18.29
Restructuring And Mergern Acquisition
—
0.00
0.00
+100.00%
-18.29
Net Income
-24.16
-232.41%
18.25
+131.75%
-57.47
+14.41%
-67.14
Pretax Income
-29.51
-236.87%
21.56
+137.59%
-57.37
+16.75%
-68.90
Net Non Operating Interest Income Expense
11.69
-5.29%
12.34
+16.27%
10.61
+168.59%
3.95
Interest Expense Non Operating
0.09
-85.10%
0.58
+5145.45%
0.01
-35.29%
0.02
Net Interest Income
11.69
-5.29%
12.34
+16.27%
10.61
+168.59%
3.95
Interest Expense
0.09
-85.10%
0.58
+5145.45%
0.01
-35.29%
0.02
Interest Income Non Operating
11.77
-8.86%
12.92
+21.59%
10.62
+167.72%
3.97
Interest Income
11.77
-8.86%
12.92
+21.59%
10.62
+167.72%
3.97
Other Income Expense
1.61
+190.09%
0.56
—
18.29
Other Non Operating Income Expenses
0.14
-74.05%
0.56
—
—
Gain On Sale Of Security
1.47
+164.14%
0.56
—
—
Tax Provision
-5.36
-261.37%
3.32
+3186.14%
0.10
+105.72%
-1.77
Tax Rate For Calcs
0.00
+17.60%
0.00
-26.71%
0.00
+719.35%
0.00
Tax Effect Of Unusual Items
0.27
+210.63%
0.09
0.00
-100.00%
0.47
Net Income Including Noncontrolling Interests
-24.16
-232.41%
18.25
+131.75%
-57.47
+14.41%
-67.14
Net Income From Continuing Operation Net Minority Interest
-24.16
-232.41%
18.25
+131.75%
-57.47
+14.41%
-67.14
Net Income From Continuing And Discontinued Operation
-24.16
-232.41%
18.25
+131.75%
-57.47
+14.41%
-67.14
Net Income Continuous Operations
-24.16
-232.41%
18.25
+131.75%
-57.47
+14.41%
-67.14
Normalized Income
-25.36
-242.66%
17.78
+130.93%
-57.47
+32.36%
-84.96
Net Income Common Stockholders
-24.16
-232.41%
18.25
+131.75%
-57.47
+14.41%
-67.14
Diluted EPS
-0.83
-233.87%
0.62
+128.97%
-2.14
+17.05%
-2.58
Basic EPS
-0.83
-225.76%
0.66
+130.84%
-2.14
+17.05%
-2.58
Basic Average Shares
28.99
+4.36%
27.78
+3.63%
26.80
+2.87%
26.05
Diluted Average Shares
28.99
-0.92%
29.25
+9.15%
26.80
+2.87%
26.05
Diluted NI Availto Com Stockholders
-24.16
-232.41%
18.25
+131.75%
-57.47
+14.41%
-67.14
Amortization
34.84
+213.69%
11.11
+23.22%
9.01
+9.04%
8.27
Amortization Of Intangibles Income Statement
34.84
+213.69%
11.11
+23.22%
9.01
+9.04%
8.27
Depreciation Amortization Depletion Income Statement
34.84
+213.69%
11.11
+23.22%
9.01
+9.04%
8.27
Depreciation And Amortization In Income Statement
34.84
+213.69%
11.11
+23.22%
9.01
+9.04%
8.27
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
578.56
+8.91%
531.24
+17.18%
453.34
+1.34%
447.33
Current Assets
361.10
+0.26%
360.15
+21.82%
295.63
+1.15%
292.29
Cash Cash Equivalents And Short Term Investments
299.50
+2.17%
293.13
+20.58%
243.10
-6.00%
258.62
Cash And Cash Equivalents
116.73
-2.49%
119.71
+21.11%
98.84
-19.61%
122.95
Other Short Term Investments
182.78
+5.39%
173.42
+20.22%
144.26
+6.32%
135.68
Receivables
43.38
-15.30%
51.22
+33.72%
38.30
+63.15%
23.48
Accounts Receivable
43.38
-15.30%
51.22
+33.72%
38.30
+63.15%
23.48
Inventory
10.25
+26.05%
8.13
+2.43%
7.94
+99.55%
3.98
Prepaid Assets
—
—
—
—
Other Current Assets
7.96
+3.72%
7.67
+21.92%
6.29
+1.37%
6.21
Total Non Current Assets
217.46
+27.11%
171.08
+8.48%
157.71
+1.72%
155.04
Net PPE
112.24
+78.99%
62.71
+66.16%
37.74
+42.43%
26.50
Gross PPE
130.53
+72.80%
75.54
+64.75%
45.85
+33.50%
34.34
Accumulated Depreciation
-18.30
-42.58%
-12.83
-58.22%
-8.11
-3.35%
-7.85
Properties
0.00
0.00
0.00
0.00
Land And Improvements
7.25
+0.00%
7.25
0.00
—
Machinery Furniture Equipment
9.57
+8.15%
8.85
+37.27%
6.45
+7.49%
6.00
Construction In Progress
51.06
+431.09%
9.61
+1409.26%
0.64
-50.04%
1.27
Other Properties
47.83
+35.81%
35.22
+22.37%
28.78
+31.39%
21.90
Leases
14.83
+1.49%
14.62
+46.31%
9.99
+93.19%
5.17
Goodwill And Other Intangible Assets
99.57
-6.26%
106.23
-9.47%
117.33
-7.13%
126.35
Goodwill
10.69
+0.00%
10.69
+0.00%
10.69
+0.00%
10.69
Other Intangible Assets
88.88
-6.97%
95.54
-10.41%
106.64
-7.79%
115.66
Non Current Accounts Receivable
1.88
+104.58%
0.92
-22.92%
1.19
+9.57%
1.09
Other Non Current Assets
3.77
+206.92%
1.23
-14.72%
1.44
+29.73%
1.11
Total Liabilities Net Minority Interest
107.68
+42.82%
75.40
+21.47%
62.07
+28.83%
48.18
Current Liabilities
68.68
+39.04%
49.39
+3.62%
47.67
+31.94%
36.13
Payables And Accrued Expenses
24.60
+108.12%
11.82
-26.51%
16.08
+85.33%
8.68
Payables
18.71
+171.13%
6.90
-35.32%
10.67
+125.51%
4.73
Accounts Payable
18.71
+171.13%
6.90
-32.79%
10.27
+117.04%
4.73
Current Accrued Expenses
5.89
+19.70%
4.92
-9.16%
5.41
+37.17%
3.95
Pensionand Other Post Retirement Benefit Plans Current
39.21
+16.08%
33.78
+13.20%
29.84
+18.14%
25.26
Total Tax Payable
—
1.08
+168.33%
0.40
+983.78%
0.04
Current Debt And Capital Lease Obligation
1.74
-10.34%
1.94
+70.89%
1.14
-36.02%
1.78
Current Debt
0.42
+50.00%
0.28
—
—
Other Current Borrowings
0.42
+50.00%
0.28
—
—
Current Capital Lease Obligation
1.32
-20.42%
1.67
+46.44%
1.14
-36.02%
1.78
Current Deferred Liabilities
—
—
—
—
Current Deferred Revenue
—
—
—
—
Other Current Liabilities
3.13
+68.97%
1.85
+205.28%
0.61
+46.02%
0.41
Total Non Current Liabilities Net Minority Interest
39.01
+49.98%
26.01
+80.56%
14.40
+19.53%
12.05
Long Term Debt And Capital Lease Obligation
35.17
+44.14%
24.40
+71.86%
14.20
+22.15%
11.62
Long Term Debt
9.64
-1.08%
9.74
—
—
Long Term Capital Lease Obligation
25.53
+74.20%
14.66
+3.23%
14.20
+22.15%
11.62
Non Current Deferred Liabilities
2.33
+45.30%
1.61
+680.10%
0.21
-51.87%
0.43
Non Current Deferred Revenue
—
—
—
—
Non Current Deferred Taxes Liabilities
2.33
+45.30%
1.61
+680.10%
0.21
-51.87%
0.43
Other Non Current Liabilities
1.50
—
—
—
Stockholders Equity
470.87
+3.30%
455.83
+16.50%
391.27
-1.97%
399.15
Common Stock Equity
470.87
+3.30%
455.83
+16.50%
391.27
-1.97%
399.15
Capital Stock
0.03
+7.14%
0.03
+3.70%
0.03
+0.00%
0.03
Common Stock
0.03
+7.14%
0.03
+3.70%
0.03
+0.00%
0.03
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
29.69
+4.22%
28.48
+3.91%
27.41
+3.23%
26.55
Ordinary Shares Number
29.69
+4.22%
28.48
+3.91%
27.41
+3.23%
26.55
Additional Paid In Capital
694.86
+5.97%
655.70
+7.58%
609.48
+8.76%
560.41
Retained Earnings
-224.28
-12.07%
-200.13
+8.36%
-218.37
-35.71%
-160.91
Gains Losses Not Affecting Retained Earnings
0.27
+16.09%
0.23
+69.12%
0.14
+135.70%
-0.38
Other Equity Adjustments
0.27
+16.09%
0.23
+69.12%
0.14
+135.70%
-0.38
Total Equity Gross Minority Interest
470.87
+3.30%
455.83
+16.50%
391.27
-1.97%
399.15
Total Capitalization
480.51
+3.21%
465.58
+18.99%
391.27
-1.97%
399.15
Working Capital
292.42
-5.90%
310.76
+25.32%
247.97
-3.20%
256.16
Invested Capital
480.93
+3.24%
465.86
+19.06%
391.27
-1.97%
399.15
Total Debt
36.91
+40.12%
26.34
+71.79%
15.34
+14.44%
13.40
Capital Lease Obligations
26.86
+64.55%
16.32
+6.43%
15.34
+14.44%
13.40
Net Tangible Assets
371.30
+6.20%
349.61
+27.62%
273.93
+0.41%
272.80
Tangible Book Value
371.30
+6.20%
349.61
+27.62%
273.93
+0.41%
272.80
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
64.35
-0.80%
64.87
+1252.97%
-5.63
+86.49%
-41.66
Cash Flow From Continuing Operating Activities
64.35
-0.80%
64.87
+1252.97%
-5.63
+86.49%
-41.66
Net Income From Continuing Operations
-24.16
-232.41%
18.25
+131.75%
-57.47
+14.41%
-67.14
Depreciation Amortization Depletion
40.77
+154.87%
16.00
+29.74%
12.33
+16.95%
10.54
Depreciation
5.93
+21.30%
4.89
+47.45%
3.32
+45.61%
2.28
Amortization Cash Flow
34.84
+213.69%
11.11
+23.22%
9.01
+9.04%
8.27
Depreciation And Amortization
40.77
+154.87%
16.00
+29.74%
12.33
+16.95%
10.54
Amortization Of Intangibles
34.84
+213.69%
11.11
+23.22%
9.01
+9.04%
8.27
Other Non Cash Items
0.15
-42.91%
0.27
-57.80%
0.64
+103.50%
-18.13
Stock Based Compensation
45.89
-8.80%
50.32
-1.76%
51.22
+41.02%
36.32
Deferred Tax
-6.23
-544.54%
1.40
+728.25%
-0.22
+88.12%
-1.88
Deferred Income Tax
-6.23
-544.54%
1.40
+728.25%
-0.22
+88.12%
-1.88
Operating Gains Losses
-1.47
-164.14%
-0.56
—
—
Gain Loss On Investment Securities
-1.47
-164.14%
-0.56
—
—
Change In Working Capital
13.60
+196.29%
-14.12
-113.05%
-6.63
-94614.29%
-0.01
Change In Receivables
6.88
+154.39%
-12.64
+15.32%
-14.93
-140.11%
-6.22
Changes In Account Receivables
6.88
+154.39%
-12.64
+15.32%
-14.93
-140.11%
-6.22
Change In Inventory
-2.14
-1009.84%
-0.19
+95.13%
-3.96
-135.83%
-1.68
Change In Prepaid Assets
-0.54
+52.36%
-1.14
-162.53%
-0.43
+64.46%
-1.22
Change In Payables And Accrued Expense
9.68
+2290.05%
-0.44
-103.56%
12.43
+53.23%
8.11
Change In Accrued Expense
6.60
+67.99%
3.93
-41.57%
6.73
-10.70%
7.53
Change In Payable
3.08
+170.40%
-4.37
-176.61%
5.71
+880.58%
0.58
Change In Account Payable
3.08
+170.40%
-4.37
-176.61%
5.71
+880.58%
0.58
Change In Other Working Capital
—
—
4.59
-46.00%
8.49
Change In Other Current Assets
1.01
-36.49%
1.58
+369.39%
-0.59
-136.54%
1.61
Change In Other Current Liabilities
-1.27
+1.09%
-1.29
-251.29%
0.85
+240.13%
-0.61
Investing Cash Flow
-60.37
-20.40%
-50.14
-209.81%
-16.18
+90.28%
-166.54
Cash Flow From Continuing Investing Activities
-60.37
-20.40%
-50.14
-209.81%
-16.18
+90.28%
-166.54
Net PPE Purchase And Sale
-35.98
-27.09%
-28.31
-108.02%
-13.61
-150.29%
-5.44
Purchase Of PPE
-36.02
-27.17%
-28.33
-107.96%
-13.62
-141.85%
-5.63
Sale Of PPE
0.04
+150.00%
0.02
+38.46%
0.01
-93.33%
0.20
Capital Expenditure
-36.02
-27.17%
-28.33
-107.96%
-13.62
-141.85%
-5.63
Net Investment Purchase And Sale
2.02
+109.25%
-21.83
-747.73%
-2.58
+98.09%
-134.69
Purchase Of Investment
-188.71
+8.27%
-205.73
-8.81%
-189.07
-40.38%
-134.69
Sale Of Investment
190.73
+3.72%
183.90
-1.39%
186.50
0.00
Net Business Purchase And Sale
-18.73
0.00
0.00
+100.00%
-26.97
Purchase Of Business
-18.73
0.00
0.00
+100.00%
-26.97
Net Other Investing Changes
-7.68
—
—
0.55
Financing Cash Flow
-6.96
-213.37%
6.14
+367.15%
-2.30
-251.68%
1.51
Cash Flow From Continuing Financing Activities
-6.96
-213.37%
6.14
+367.15%
-2.30
-251.68%
1.51
Net Issuance Payments Of Debt
0.07
-99.24%
9.90
+7073.94%
-0.14
-16.39%
-0.12
Issuance Of Debt
0.19
-98.10%
10.00
0.00
0.00
Repayment Of Debt
-0.12
-18.56%
-0.10
+31.69%
-0.14
-16.39%
-0.12
Long Term Debt Issuance
0.19
-98.10%
10.00
0.00
0.00
Long Term Debt Payments
-0.12
-18.56%
-0.10
+31.69%
-0.14
-16.39%
-0.12
Net Long Term Debt Issuance
0.07
-99.24%
9.90
+7073.94%
-0.14
-16.39%
-0.12
Net Common Stock Issuance
—
—
—
—
Proceeds From Stock Option Exercised
4.62
-7.52%
5.00
+67.83%
2.98
-10.44%
3.33
Net Other Financing Charges
-11.66
-33.04%
-8.76
-70.67%
-5.13
-204.15%
-1.69
Changes In Cash
-2.98
-114.28%
20.87
+186.56%
-24.11
+88.34%
-206.69
Beginning Cash Position
119.71
+21.11%
98.84
-19.61%
122.95
-62.70%
329.63
End Cash Position
116.73
-2.49%
119.71
+21.11%
98.84
-19.61%
122.95
Free Cash Flow
28.33
-22.48%
36.54
+289.85%
-19.25
+59.30%
-47.29
Interest Paid Supplemental Data
0.06
-86.41%
0.43
+3845.45%
0.01
-31.25%
0.02
Income Tax Paid Supplemental Data
1.60
-36.04%
2.50
+1164.14%
0.20
+65.00%
0.12
Amortization Of Securities
-4.22
+36.89%
-6.68
-21.74%
-5.49
-301.39%
-1.37
Common Stock Issuance
—
—
—
—
Issuance Of Capital Stock
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category